Remicade
Ailment: Crohn’s Disease
U.S. Sales: $4.2 billion
Owner: Johnson & Johnson
Administered via IV infusion in a doctor’s office or hospital outpatient facility, Remicade stops the inflammation of the GI tract which leads to flare ups of Crohn’s Disease. The annual cost per patient of this drug runs about $24,000.
